All Stories

  1. Impact of high myopia on visual disability and its causes in a Spanish cohort
  2. A comprehensive dataset of pattern electroretinograms for ocular electrophysiology research
  3. Clinical exome analysis and targeted gene repair of the c.1354dupT variant in iPSC lines from patients with PROM1-related retinopathies exhibiting diverse phenotypes
  4. Clinical and genetic characterization of patients with eye diseases included in the Spanish Rare Diseases Patient Registry
  5. Protocolo de tratamiento del edema macular quístico asociado a retinosis pigmentaria y otras distrofias hereditarias de la retina
  6. Ala®sil chemical characterization and toxicity evaluation: an example of the need for the Medical Device Regulation 2017/745
  7. A minimum specification dataset for liquid ocular endotamponades: recommendations by a European expert panel
  8. Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy
  9. INTRAOCULAR EMULSION OF SILICONE OIL (ITEMS) GRADING SYSTEM
  10. Evaluación de signos tomográficos no exudativos en casos de degeneración macular asociada a la edad de tipo exudativo
  11. Impact of COVID-19 Confinement on Quality of Life of Patients with Age-Related Macular Degeneration: A Two-Wave Panel Study
  12. Does PLEX® Elite 9000 OCT Identify and Characterize Most Posterior Pole Lesions in Highly Myopic Patients?
  13. Gene editing strategy for development of an inherited retinal dystrophy model based on iPSC‐derived photoreceptors with mutation in the PROM1 gene
  14. Neuroprotection in ophthalmology. Targets in the most frequent diseases. A clinician's point of view
  15. Hair cortisol level as a molecular biomarker in retinitis pigmentosa patients
  16. Pathophysiology of Age-Related Macular Degeneration. Implications for Treatment
  17. Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration
  18. Long-term visual pathway alterations after elemental mercury poisoning: report of a series of 29 cases
  19. Cell Replacement Therapy for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges
  20. Monochromatic higher order aberrations in highly myopic eyes with Staphyloma
  21. Cell Therapy Replacement for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges
  22. Phenotypic Differences in a PRPH2 Mutation in Members of the Same Family Assessed with OCT and OCTA
  23. Descriptive Study of a Cohort of 488 Patients with Inherited Retinal Dystrophies
  24. Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid
  25. Silicone microbubbles after anti‐vascular endothelial growth factor injections in patients with wet age‐related macular degeneration: incidence, quantification and secondary optical coherence tomography artfacts
  26. Visual Pathway Alterations after Severe Acute Occupational Elemental Mercury Poisoning: Report of a Series of 29 Cases
  27. Early Detection of Incipient Retinal Pigment Epithelium Atrophy Overlying Drusen with Fundus Autofluorescence vs. Spectral Domain Optical Coherence Tomography
  28. Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD)
  29. PRPH2-Related Retinal Diseases: Broadening the Clinical Spectrum and Describing a New Mutation
  30. Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis
  31. Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases
  32. Chemical compounds causing severe acute toxicity in heavy liquids used for intraocular surgery
  33. Reliability of colour perimetry to assess macular pigment optical density in age-related macular degeneration
  34. Chemical Considerations Regarding the H-Value Methodology and Its Relation With Toxicity Determination
  35. Development and evaluation of a head-mounted display system based on stereoscopic images and depth algorithms for patients with visual impairment
  36. Diagnostic and Therapeutic Challenges
  37. Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: failure of another indirect cytotoxicity analysis
  38. Comparison between direct contact and extract exposure methods for PFO cytotoxicity evaluation
  39. Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab
  40. ACUTE RETINAL DAMAGE AFTER USING A TOXIC PERFLUORO-OCTANE FOR VITREO-RETINAL SURGERY
  41. El problema de la toxicidad aguda de algunos perfluoro-octanos
  42. Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review
  43. Clinical Characterization and Frequency of Observation of Hereditary Retinal Diseases: Multicentric Study in Panama in 2012-2013
  44. CopyMean: A new method to predict monotone missing values in longitudinal studies
  45. Erratum
  46. Patient participation in the development of a clinical guideline for inherited retinal dystrophies
  47. Predictors of Macular Atrophy Detected by Fundus Autofluorescence in Patients With Neovascular Age-Related Macular Degeneration After Long-Term Ranibizumab Treatment
  48. X-Linked retinoschisis associated to a novel intragenic microdeletion: case report
  49. Control of disability glare by means of electrochromic filtering glasses: A pilot study
  50. Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT)
  51. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases
  52. Progression of Retinal Pigment Epithelial Atrophy in Antiangiogenic Therapy of Neovascular Age-Related Macular Degeneration
  53. BAX and BCL‐2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: the Retina 4 project
  54. Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
  55. Loss of Visual Acuity after Successful Surgery for Macula-On Rhegmatogenous Retinal Detachment in a Prospective Multicentre Study
  56. Vision-Threatening Lesions Developing with Longer-Term Follow-up after Treatment of Neovascular Age-Related Macular Degeneration
  57. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain
  58. Quantitative SD-OCT Imaging Biomarkers as Indicators of Age-Related Macular Degeneration Progression
  59. Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables
  60. Management of significant reactivation of old disciform scars in wet Age-Related Macular Degeneration
  61. Growth of Geographic Atrophy on Fundus Autofluorescence and Polymorphisms ofCFH,CFB,C3,FHR1-3, andARMS2in Age-Related Macular Degeneration
  62. Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
  63. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
  64. Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
  65. The T309G MDM2 Gene Polymorphism Is a Novel Risk Factor for Proliferative Vitreoretinopathy
  66. Prediction of Age-related Macular Degeneration in the General Population
  67. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
  68. EXTERNAL VALIDATION OF EXISTING FORMULAS TO PREDICT THE RISK OF DEVELOPING PROLIFERATIVE VITREORETINOPATHY
  69. Evolución clínica de pacientes con degeneración macular asociada a la edad de tipo exudativo-hemorrágico tratados con ranibizumab. Estudio Eye2Eye
  70. General Practitioners´ knowledge gaps regarding Age Related Macular Degeneration and effectiveness of their e-learning training
  71. A Genetic Case-Control Study Confirms the Implication ofSMAD7andTNF Locusin the Development of Proliferative Vitreoretinopathy
  72. The p53 Codon 72 Polymorphism (rs1042522) Is Associated with Proliferative Vitreoretinopathy
  73. Retinal Pigment Epithelial Cell Loss Assessed by Fundus Autofluorescence Imaging in Neovascular Age-related Macular Degeneration
  74. Ocular Pain After Intravitreal Injection
  75. A New Manual Retinal Thickness Measurement Protocol to Evaluate High Myopia Patients
  76. Patient-Reported Outcomes in Spanish Patients Diagnosed with Bilateral Age-Related Macular Degeneration
  77. Autofluorescence Images with Carl Zeiss versus Topcon Eye Fundus Camera: A Comparative Study
  78. Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development
  79. Variations in Functional and Anatomical Outcomes and in Proliferative Vitreoretinopathy Rate along a Prospective Collaborative Study on Primary Rhegmatogenous Retinal Detachments: The Retina 1 Project—Report 4
  80. E‐learning strategies to improve general practitioners’ knowledge of age‐related macular degeneration
  81. Relevance of Complement Factor H–Related 1 (CFHR1) Genotypes in Age-Related Macular Degeneration
  82. Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration Treated with Antiangiogenic Drugs: A Controlled Study with Long Follow-Up
  83. Pathology Associated with Optical Coherence Tomography Macular Bending due to either Dome-Shaped Macula or Inferior Staphyloma in Myopic Patients
  84. Sjogren-Larsson Syndrome
  85. Sjögren-Larsson Syndrome
  86. A propensity score matching application: indications and results of adding scleral buckle to vitrectomy: The Retina 1 Project: Report 3
  87. Training and professional profile of retinologists in Spain: Retina 2 project, Report 4
  88. Genética y DMAE: del laboratorio a la consulta
  89. A Strong Genetic Association between the Tumor Necrosis Factor Locus and Proliferative Vitreoretinopathy: The Retina 4 Project
  90. Genetic association study of age-related macular degeneration in the Spanish population
  91. Benign Fleck Retina
  92. Diagnostic and Therapeutic Challenges
  93. PRPH2 (Peripherin/RDS) Mutations Associated with Different Macular Dystrophies in a Spanish Population: A New Mutation
  94. Formación y actividad clínica de los retinólogos en España: un primer acercamiento: Proyecto retina 2. Análisis descriptivo
  95. DIAGNOSTIC AND THERAPEUTIC CHALLENGES
  96. Surgical outcomes for primary rhegmatogenous retinal detachments in phakic and pseudophakic patients: the Retina 1 Project--report 2
  97. Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1
  98. Diagnostic and Therapeutic Challenges
  99. OCT FINDINGS IN TORPEDO MACULOPATHY
  100. El impacto de la Ley de Dependencia en los pacientes con baja visión
  101. Photodynamic Therapy for Subfoveal and Juxtafoveal Choroidal Neovascularization Associated with Punctate Inner Choroidopathy
  102. Complement Factor H
  103. Atypical Myopic Retinoschisis
  104. Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization
  105. Burden of illness of bilateral neovascular age-related macular degeneration in Spain
  106. Intraretinal Immunohistochemistry Findings in Proliferative Vitreoretinopathy with Retinal Shortening
  107. Reading comparative study: Electronic vs. conventional devices
  108. Monocromatismo de conos azules ligado a X: Una familia afecta
  109. Complicaciones corneales epiteliales de las vitrectomías: estudio retrospectivo
  110. Acortamiento retinado: la forma más grave de la vitreorretinopatía proliferante (VRP)
  111. Roturas retinianas iatrogénicas en las vitrectomías: estudio retrospectivo
  112. Analysis ofABCA4in mixed Spanish families segregating different retinal dystrophies
  113. Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss
  114. Pharmacokinetics of 0.5 mg of a Single and a Multiple Dose of Intravitreal Vancomycin in Infected Rabbit Eyes
  115. Further Evidence for an Association of ABCR Alleles with Age-Related Macular Degeneration
  116. Sjo ̈gren-Larsson syndrome
  117. Pharmacokinetics of Intravitreal Vancomycin in Normal and Infected Rabbit Eyes
  118. High-performance liquid chromatographic determination of vancomycin in rabbit serum, vitreous and aqueous humour after intravitreal injection of the drug
  119. New Electro-Optic and Display Technology for Visually Disabled People